AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: It is permitted which can be interchangeable with prednisone. It will be given by oral administration of 24mg/day from beginning and be lowed dosage during the treatment of 24 weeks.
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: It is permitted which can be interchangeable with cyclophosphamide or tacrolimus. It will be given by oral administration of 0.5g twice a day for 24 weeks.
Study NCT05666336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: It is permitted which can be interchangeable with cyclophosphamide or mycophenolate mofetil. It will be given by oral administration of 1mg twice a day for 24 weeks.
Study NCT05717842 — intervention group
Intervention type: RADIATION
Intervention: Nuclear Medicine Scan
Description: Mercaptoacetyltriglycine 3 (Mag 3) Nuclear Medicine Scan
Study NCT05784636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BiPAP ventilation
Description: Patients were first treated with HFNC (High-flow nasal cannula) on the basis of conventional treatment. The initial parameters were temperature: 31-37 °C, flow rate: 30-40l /min, maintaining SpO2>92%, adjusting oxygen concentration according to blood oxygen saturation, and treatment duration was 24 h. After 24 h, patients were treated with non-invasive ventilator-assisted ventilation BiPAP mode until discharge.
Study NCT05784636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: On the basis of conventional treatment, patients were first administered a noninvasive ventilator with the following initial parameters. BiPAP mode with an initial inspiratory pressure (IPAP) of 8-15 cmH2O and an initial expiratory pressure (EPAP) of 4-8 cmH2O. These parameters were adjusted according to the patient's specific conditions. After 24 hours of treatment, patients received HFNC (High-flow nasal cannula) until discharge.
Study NCT04227314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast: 30 mg twice daily during a 12 week double blind placebo controlled period, then 30 mg twice daily during an additional 12 week active treatment period
Study NCT04227314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
Study NCT06245876 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection
Study NCT04878770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical corticosteroids
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
Study NCT04878770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic cyclosporine
Description: Systemic cyclosporine A (CsA) is an immunosuppressive therapy and is a registered treatment for AD in adults. According to national guidelines, CsA is the first choice for systemic treatment in children with moderate-to-severe AD.~For CsA a starting dose of 4-5mg/kg/day is administered orally and then tapered down to 2-3mg/kg/day depending on clinical effect. Two doses will be taken at two fixed times per day. Treatment with systemic CsA will be continued for a total of 6 months.
Study NCT04878770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic dupilumab
Description: Dupilumab (DUPIXENT) is indicated for the treatment of children of 6 years and older with moderate-to-sever atopic dermatitis whos disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. rm: Active Comparator: Systemic dupilumab Dupilumab (DUPIXENT) is administered as a solution by subdermal injection according to national guidelines, based on age and body weight.
Study NCT06399523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR therapy
Description: Participants this group received additional VR therapy , with a total 20 sessions over a period of 4 weeks based on routine treatment.
Study NCT06399523 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VR sham
Description: Participants in this group received additional VR sham(health education videos,a total of 20 health education videos over a period of 4 weeks) under virtual reality conditions on the basis of routine treatment.
Study NCT04852328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUE-101
Description: CUE Biopharma will supply CUE-101, which will be provided free of charge to the patient.
Study NCT04508400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant,ondansetron, dexamethasone
Description: Participants will randomly assigned 1:1 to receive double-blind study drug ( fosaprepitant plus ondansetron with dexamethasone OR placebo plus ondansetron with dexamethasone). Fosaprepitant or placebo to fosaprepitant were supplied and administered in a blinded manner.
Study NCT04508400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ondansetron with dexamethasone
Description: placebo plus ondansetron with dexamethasone
Study NCT06490627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 5-6mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period.
Study NCT06490627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide is being investigated for its therapeutic efficacy and safety profile in transfusion-dependent beta thalassemia patients.~Participants in this arm received thalidomide. Thalidomide was administered orally at a dosage of 7-8mg/kg/day. The medication was taken continuously or on a specified schedule (e.g., daily,) for the duration of the study period, which lasted 2 years. Participants were monitored for adherence to the medication regimen and for any adverse effects throughout the intervention period.
Study NCT06175403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Intravenous administration of dose titrated from 10 µg·kg FFM-1·min-1 to 30 µg·kg for approximately 4.5 hours on one occasion
Study NCT04405115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Assessment
Description: Geriatric Assessment Visit
Study NCT05085951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 mm CRE balloon
Description: Endoscopic balloon that is used to dilate pylorus
Study NCT05085951 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: OGD
Description: OGD (No dilatation)
Study NCT05522179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutraHeal
Description: Receive NutraHeal (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
Study NCT05522179 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NutraHeal Plus
Description: Receive NutraHeal Plus (2 capsules twice a day) as a dietary supplement beginning 1 week prior to surgery and extending to 3 weeks after foot surgery.
Study NCT06156436 — intervention group
Intervention type: DEVICE
Intervention: ResAppDx v.20
Description: Software application used to aid diagnosis of respiratory disorders
Study NCT05275348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Enhance Fitness
Description: Tele-Enhance Fitness (tele-EF) is a community-based exercise program for older adults. It is a supervised group exercise program that will meet virtually 3 times a week for 1 hour for 4 months. Each tele-EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Tele-EF classes will be led by an instructor trained in administering EF through a virtual format. EF instructors will be able to monitor and correct participant's movements through videoconference. All tele-EF classes are monitored by a spotter who watches participants exercise using gallery mode.
Study NCT05275348 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Enhance Fitness
Description: Enhance Fitness is a community-based exercise program for older adults. It is a supervised group exercise program that will meet in person 3 times a week for 1 hour for 4 months. Each EF class uses a standardized format that includes a 5-minute warm-up phase, 25 minutes of moderate-intensity aerobic conditioning/walking, 20 minutes of progressive strength training, and 10 minutes of cool down involving flexibility and balance exercises. Strength training involves progressive resistance exercises, using adjustable 1- to 10-pound ankle and wrist weights. Classes will be led by an instructor trained in administering Enhance Fitness.
Study NCT04278963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YinHu QingWen Decoction
Description: YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Study NCT04278963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YinHu QingWen Decoction(low dose)
Description: This intervention is given as 10% dose of YinHu QingWen Decoction (Granula).The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Study NCT04278963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chinese medicine treatment
Description: This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days.
Study NCT04278963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
Study NCT04278963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
Study NCT04278963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard western medicine treatment
Description: Standard western medicine treatment is according to the protocol of treatment of CoVID-19 infection according to guideline appoved by National Health Commission of China.
Study NCT04745039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopatch System
Description: The patch system for aortic dissection tear is composed of a dissection tear patch system and an adjustable bend conveyor. The patch system is composed of a patch and a conveying steel cable. The patch is pre-installed on the conveying steel cable.
Study NCT06125769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Description: Patients will undergo liver transplantation according to the standard procedures of the institutional Center's protocol (cadaveric or living donor transplantation, whole or partial liver). Liver transplantation is preceded by an exploratory laparotomy with clinical evaluation and frozen section examination of lymph nodes in the hepatoduodenal ligament and along the common hepatic artery/celiac axis.
Study NCT04092348 — intervention group
Intervention type: OTHER
Intervention: complete blood count
Description: 1. total RNA is isolated from fresh blood samples~2. RNA is converted into complementary DNA c.DNA~3. cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene.
Study NCT04858451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RESP301
Description: A single RESP301 dose administered at a study site to assess tolerability.~In patients who experience a flare-up during the study period, self-administered RESP301 treatment for 7 days, 3 times a day.
Study NCT05401084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient diet changes.
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-1
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-1
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-3
Description: Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-3
Description: Treatment with topical spray twice-daily (BID) BB2603-3: 0.03% terbinafine
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB2603-10
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
Study NCT04188574 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BB2603-10
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
Study NCT04188574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
Study NCT04188574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Treatment with topical spray twice-daily (BID): 0.3% polyhexanide/ 20% ethanol/ water formulation.
Study NCT04922840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HIIT)
Description: 12 week intervention: Two weekly sessions of 35-40 min exercise: 10 min warm-up, followed by 4x4 min at 90-95% peak heart rate (HRpeak) interspaced by 2-3 min active breaks at 60-70% HRpeak and a third weekly session with continuous exercise for a minimum of 40 min at moderate intensity.
Study NCT05425615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS
Study NCT05425615 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS
Study NCT05425615 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Deymed DuoMag XT-100 rTMS
Study NCT05160155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Serratus anterior plane block will be performed unilaterally, under US guidance.
Study NCT05160155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Block
Description: Intercostal Block will be performed unilaterally, under US guidance.
Study NCT05338177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunosuppression reduction
Description: participants stop mycophenolate or azathioprine one week before additional vaccine dose. Overall medication is stopped for two weeks.
Study NCT05338177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No immunosuppression reduction
Description: participants do not alter immunosuppresion
Study NCT05171348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM326
Description: a humanized monoclonal antibody
Study NCT05171348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06466304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: children patients with BTM accounted 20 children will receive two session per day of training by threshold inspiratory muscle trainer ( for six day per week for 12 weeks). the session will contain six sets of inspiratory muscle training and the one set will contain five respiratory cycles
Study NCT05018039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborarive Care Model
Description: Collaborative care involves three professionals: a physical health care provider (physiotherapist or occupational therapist), a mental health care provider and a case manager. The case manager will work closely with the patient to identify the mental health support necessary. This may involve appointments with a psychologist or psychiatrist as part of their musculoskeletal treatment.~The case manager will define a treatment plan and organise appointments with the patients and monitor their progress using validated questionnaires, adjusting their mental or physical care support when required. This professional will also monitor patients' attendance and support managing their appointments and routinely update the clinical team on patient progress, and relaying information back to the clinical team. This model of care will work in parallel to the regular musculoskeletal appointments (usual care).
Study NCT05376475 — intervention group
Intervention type: DEVICE
Intervention: Infrared video-audio camera
Description: Wyze Cam V2 by Wyze Labs, Inc., Seattle, USA
Study NCT05376475 — intervention group
Intervention type: DEVICE
Intervention: Level III home sleep apnea test
Description: NightOwl® by Ectosense, Leuven, Belgium
Study NCT05376475 — intervention group
Intervention type: DEVICE
Intervention: Maternal-fetal transabdominal electrocardiographic heart rate monitor
Description: The Monica AN24 Antenatal Fetal Holter by Monica Healthcare, Nottingham, UK
Study NCT05376475 — intervention group
Intervention type: DEVICE
Intervention: Pressure sensing mat
Description: Tactilus® V Series Mattress Pressure Monitoring System by Sensor Products Inc., Madison, USA
Study NCT06489587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants given 40 grams of glucose in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
Study NCT06489587 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants given 40 grams of creatine in total to be taken over 2 days, in 5-gram servings (4 capsules), 4 times per day.
Study NCT05177653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GIP receptor antagonist (GIP(3-30)NH2)
Study NCT05177653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GLP-1 receptor antagonist (exendin(9-39)NH2)
Study NCT05177653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous infusion
Description: GIP(3-30)NH2 and exendin(9-39)NH2
Study NCT05177653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion
Description: Saline
Study NCT06410365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Comparison of intravenous and intrathecal route of dexmedetomidine
Study NCT05289570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: 500 mg of voxelotor will be administered two times a day (for a total daily dose of 1000 mg per day) for 5 days. This dose may increase to a total maximum daily dose of 1500 mg (500 mg three times a day) if subject tolerates initial dose as determined by Principal Investigator (PI).
Study NCT06264427 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Description: Screening for MODY diabetes. Diabetic treatment will be adjusted based on the participant's diabetic genotype.
Study NCT06264427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VAGUS
Description: To examine for Cardiovasculare Autonomic Neuropathy participants will be tested with the handheld Vagus device (Medicus Engineering, Aarhus, Denmark). Participants are instructed to perform three cardiovascular reflex tests (CARTs) after lying still in supine position for 5 minutes to record heart rate at rest. CARTs include supine-to-upright position, deep-breathing, and valsalva maneuver. From each CART the ratio based on the shortest and longest R-R-interval at predefined timepoints in the recording is used to assess the possibility of CAN
Study NCT06264427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NightOwl
Description: Participants will be examined for sleep apnea for 3 nights using the NightOwl (Ectosense, Belgium) device, which measuring Peripheral Arterial Tonometry (PAT) in the index finger. The results of the examination will is uploaded via the patient's smartphone to an online platform accessible to healthcare providers. Participants with signs of sleep apnea will receive a confirmatory cardiorespiratory monitoring using the Nox T3s (Noxturnal, ResMed), and the results will be compared.